Oncology Biosimilars Market – Size, Share, Outlook, and Opportunity Analysis 2018 - 2026

1. Oncology Biosimilars Oncology Biosimilars Market Size, Share, Market Size, Share, Trend, Outlook, Future Growth Analysis Trend, Outlook, Future Growth Analysis And Synthesis 2018 - 2026 And Synthesis 2018 - 2026 Biosimilar is a biological product that resembles a reference product and is not difference from the already approved reference product. These are relatively cheaper than branded or approved products. Several biologics for oncology have already lost their patents, and some are in its period of expiry. As more products are expected to lose patents, biosimilar is expected to gain popularity. Leading generic players such as Mylan N.V., Teva Pharmaceutical Industries Ltd, Allergan Plc, Sandoz (a Novartis International AG’s division) are expected to capitalize on these patent expiries and may establish themselves as dominating players in oncology biosimilars market. Get Free PDF Brochure of Research Report: Get Free PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1305 https://www.coherentmarketinsights.com/insight/request-pdf/1305 Rapid approval of biosimilars for oncology is expected to be a major driving factor for growth of the Rapid approval of biosimilars for oncology is expected to be a major driving factor for growth of the oncology biosimilars market over the forecast period oncology biosimilars market over the forecast period There was about a decade gap in approval of first biosimilars in two key markets, Europe and the U.S. First biosimilar was approved in 2006 in Europe, however, in the U.S. first product was approved in 2015. But since approving the first biosimilar, the FDA has approved five products in 2017. Out of these five biosimilars, two were approved for oncology. First, oncology biosimilar Mvasi (bevacizumab-awwb) received approval in September 2017, and second one, Ogivri (trastuzumab) was approved in December 2017. In Europe, both of the products have been approved, and Mvasi received approval from European Commission in January 2018. Moreover, there are number of biosimilar application pending in the U.S. and Europe. For Herceptin (trastuzumab) alone, there are around four application pending in the FDA. These four application are from Amgen and Allergan, Celltrion and Teva, Pfizer, and Samsung Bioepis. Recent approval of products, and potential approval in next few years is expected to boost the market growth over the forecast period.

2. North America is expected to dominate the oncology biosimilars market over the forecast period North America is expected to dominate the oncology biosimilars market over the forecast period On the basis of region, oncology biosimilars market by Coherent Market Insights is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to be the dominant market over the forecast period. U.S. FDA approved first biosimilar in 2015, almost a decade later than first biosimilar approval in Europe. However, since 2015, the number of approved products has increased rapidly. This is expected to be factor for growth of the market in North America. Moreover, currently there are number of products in pipeline, which may receive approval from the FDA over the forecast period. For instance, Pfizer Inc. — a U.S.-based company — has three biosimilar products (i.e. PF-05280014, PF-05280586 and PF-06439535) for oncology in Phase 3. Report includes chapters which deeply display the following deliverable about industry : Report includes chapters which deeply display the following deliverable about industry : • Oncology Biosimilars Market Research Objective and Assumption • Oncology Biosimilars Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Oncology Biosimilars Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Oncology Biosimilars Market, By Regions • Oncology Biosimilars Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Oncology Biosimilars Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Oncology Biosimilars Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Oncology Biosimilars Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion

3. Oncology Biosimilars Market - Competitor Analysis Oncology Biosimilars Market - Competitor Analysis Key players operating in the global oncology biosimilars market include Amgen Inc., Allergan, Plc, Mylan N.V., Samsung Bioepis Co., Ltd., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Celltrion Healthcare, Novartis International AG, Biogen Idec, Inc., and Biocon Limited. Oncology Biosimilars Market Taxonomy Oncology Biosimilars Market Taxonomy By Cancer Type: By Cancer Type: Lung Cancer • Colorectal cancer • Cervical Cancer • Breast Cancer • Kidney cancer • Stomach cancer • Brain Cancer • Others • By Product Type: By Product Type: Monoclonal Antibody • Immunomodulators • Others • Browse In-Depth Analysis Research Report @ Browse In-Depth Analysis Research Report @ https://www.coherentmarketinsights.com/ongoing- https://www.coherentmarketinsights.com/ongoing- insight/oncology-biosimilars-market-1305 insight/oncology-biosimilars-market-1305

4. About Coherent Market Insights About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action- ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: Email: sales@coherentmarketinsights.com sales@coherentmarketinsights.com